Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors

NCT00687934 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
53
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Synta Pharmaceuticals Corp.